

Results of Annual General Meeting

Melbourne, Australia – Tryptamine Therapeutics Limited ('Tryp', 'TYP' or the 'Company') (ASX: TYP), a clinical-stage biotechnology company, advises that its Annual General Meeting was held today at 4.00 pm AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that details of the resolutions and the proxies received in respect of each resolution are included in the attached document. All resolutions were carried by the requisite majorities.

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

Investor & Media Contact

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@trypttherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Tryptamine Therapeutics Limited

Tryp is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome.

Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit www.trypttherapeutics.com.

Register for updates

The Company encourages investors to register their details with Automic Group investor portal. This also provides shareholders with the opportunity to elect communication methods to electronic only. This can be done by:

- Go to investor.automic.com.au
- If you're an existing user, log in with your username and password
- If you're a new user, click 'register', select 'Tryptamine Therapeutics Limited'. Enter your Holding Number and postcode of the registered address on your holding. If your address is outside Australia, select the country. Follow the prompts to set up a username and password.
- Once you have created your account, you will need to update your communication method by clicking 'my details' under the 'profile' section of the investor portal account, then navigating to 'communication preferences' and select 'electronic only'

Risks associated with Psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Disclosure of Proxy Votes

Tryptamine Therapeutics Limited

Annual General Meeting

Thursday, 13 November 2025



GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 NON-BINDING RESOLUTION TO ADOPT REMUNERATION REPORT	P	64,967,461	64,459,555 99.22%	53,738 0.08%	0	454,168 0.70%	64,913,723 99.92%	53,738 0.08%	0	-
2 ELECTION OF MR HERWIG JANSSEN AS A DIRECTOR	P	180,681,579	180,076,452 99.67%	7,795 0.00%	4,800	597,332 0.33%	214,423,784 100.00%	7,795 0.00%	4,800	Carried
3 ELECTION OF DR DANIEL TILLET AS A DIRECTOR	P	180,681,579	180,076,452 99.67%	7,795 0.00%	4,800	597,332 0.33%	214,423,784 100.00%	7,795 0.00%	4,800	Carried
4 RE-ELECTION OF MR GAGE JULL AS A DIRECTOR	P	180,686,379	180,074,565 99.66%	14,482 0.01%	0	597,332 0.33%	214,421,897 99.99%	14,482 0.01%	0	Carried
5 CHANGE OF COMPANY NAME	P	177,947,179	172,868,398 97.15%	13,289 0.01%	2,739,200	5,065,492 2.85%	211,683,890 99.99%	13,289 0.01%	2,739,200	Carried
6 APPROVAL OF 10% PLACEMENT FACILITY	P	180,681,579	180,094,273 99.67%	133,138 0.07%	4,800	454,168 0.25%	214,298,441 99.94%	133,138 0.06%	4,800	Carried
7 ADOPTION OF EMPLOYEE SECURITIES INCENTIVE PLAN	P	64,840,249	59,677,061 92.04%	4,565,856 7.04%	127,212	597,332 0.92%	60,274,393 92.96%	4,565,856 7.04%	127,212	Carried
8 APPROVAL FOR ISSUE OF OPTIONS TO MR HERWIG JANSSEN	P	64,842,127	58,633,478 90.42%	5,611,317 8.65%	125,334	597,332 0.92%	59,230,810 91.35%	5,611,317 8.65%	125,334	Carried



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 APPROVAL FOR ISSUE OF OPTIONS TO MR JASON CARROLL	P	59,842,127	53,633,478 89.62%	5,611,317 9.38%	5,125,334	597,332 1.00%	54,230,810 90.62%	5,611,317 9.38%	5,125,334	Carried
10 APPROVAL FOR ISSUE OF OPTIONS TO MR CHRIS NTOUMENOPOULOS	P	64,842,127	56,653,478 87.37%	7,591,317 11.71%	125,334	597,332 0.92%	57,250,810 88.29%	7,591,317 11.71%	125,334	Carried
11 APPROVAL FOR ISSUE OF OPTIONS TO MR GAGE JULL	P	64,842,127	58,633,478 90.42%	5,611,317 8.65%	125,334	597,332 0.92%	59,230,810 91.35%	5,611,317 8.65%	125,334	Carried
12 APPROVAL FOR ISSUE OF OPTIONS TO DR DANIEL TILLET	P	64,842,127	58,633,478 90.42%	5,611,317 8.65%	125,334	597,332 0.92%	59,230,810 91.35%	5,611,317 8.65%	125,334	Carried
13 APPROVAL FOR ISSUE OF SHARES TO A DIRECTOR – HERWIG JANSSEN	P	64,842,127	59,433,478 91.66%	4,811,317 7.42%	125,334	597,332 0.92%	60,030,810 92.58%	4,811,317 7.42%	125,334	Carried
14 RE-ADOPTION OF PROPORTIONAL TAKEOVER PROVISIONS	P	180,605,101	179,962,520 99.64%	45,249 0.03%	81,278	597,332 0.33%	214,309,852 99.98%	45,249 0.02%	81,278	Carried
15 APPROVAL FOR ISSUE OF OPTIONS TO UNRELATED PARTIES	P	176,306,645	169,897,996 96.37%	5,811,317 3.30%	4,379,734	597,332 0.34%	204,245,328 97.23%	5,811,317 2.77%	4,379,734	Carried
16 APPOINTMENT OF AUDITOR	P	173,371,183	173,083,183 99.83%	0 0.00%	0	288,000 0.17%	207,121,183 100.00%	0 0.00%	0	Carried

